Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) Net Margin (2017 - 2025)

Aclaris Therapeutics (ACRS) has 9 years of Net Margin data on record, last reported at 1629.34% in Q4 2025.

  • For Q4 2025, Net Margin fell 57006.0% year-over-year to 1629.34%; the TTM value through Dec 2025 reached 878.33%, down 16267.0%, while the annual FY2025 figure was 878.33%, 17285.0% down from the prior year.
  • Net Margin reached 1629.34% in Q4 2025 per ACRS's latest filing, down from 464.69% in the prior quarter.
  • Across five years, Net Margin topped out at 23.03% in Q4 2023 and bottomed at 1702.25% in Q2 2023.
  • Average Net Margin over 5 years is 909.68%, with a median of 1023.23% recorded in 2021.
  • Peak YoY movement for Net Margin: crashed -158712bps in 2021, then skyrocketed 130503bps in 2024.
  • A 5-year view of Net Margin shows it stood at 1525.18% in 2021, then surged by 75bps to 375.07% in 2022, then surged by 94bps to 23.03% in 2023, then crashed by -4499bps to 1059.29% in 2024, then crashed by -54bps to 1629.34% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 1629.34% in Q4 2025, 464.69% in Q3 2025, and 922.34% in Q2 2025.